Gene info: ID 345

Gene: APOC3

GENE ID: 345

Synonyms: APOCIII

Description: apolipoprotein C3

Gene type: protein-coding

Location: 11q23.3

dbXrefs: Ensembl:ENSG00000110245 MIM:107720 Vega:OTTHUMG00000046115 UniprotKB:P02656

RefSeq: NG_008949.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 23

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.703e-2 (AD) 3.047e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
APCS	0.706
AGXT	0.684
FGA	0.659
APOA2	0.654
ALB	0.632
HP	0.629
FGG	0.621
CRP	0.611
APOH	0.6
FGB	0.595

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
TRIML2	-0.252
ANKRD61	-0.238
FLG	-0.235
AGBL1	-0.234
NLRP14	-0.234
TRPM5	-0.234
AHRR	-0.232
DNAH2	-0.229
CCDC65	-0.229
CNGB1	-0.228

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB09130	Copper	Small Molecule	7440-50-8	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C026486	1,2,5,6-dibenzanthracene	"[Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene] affects the expression of APOC3 mRNA"	17690111
C012277	1,2-diamino-4-nitrobenzene	"1,2-diamino-4-nitrobenzene results in decreased expression of APOC3 mRNA"	17070881
C041507	1-methylphenanthrene	[Benzo(a)pyrene co-treated with 1-methylphenanthrene] affects the expression of APOC3 mRNA	17690111
C035314	1-nitropropane	1-nitropropane results in increased expression of APOC3 mRNA	17070881
C010914	2,4-diaminotoluene	"2,4-diaminotoluene results in decreased expression of APOC3 mRNA"	17070881
C025235	2,6-diaminotoluene	"2,6-diaminotoluene results in decreased expression of APOC3 mRNA"	17070881
C014706	2-nitro-4-phenylenediamine	2-nitro-4-phenylenediamine results in decreased expression of APOC3 mRNA	17070881
C016617	2-nitropropane	2-nitropropane results in decreased expression of APOC3 mRNA	17070881
C575631	4-(4-(2,4-dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy)-3-trifluoromethylbenzonitrile	"4-(4-(2,4-dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy)-3-trifluoromethylbenzonitrile affects the expression of APOC3 mRNA"	21218783
C028676	4-acetylaminofluorene	4-acetylaminofluorene results in decreased expression of APOC3 mRNA	17070881
C029370	4-toluidine	4-toluidine results in decreased expression of APOC3 mRNA	27638505
D000082	Acetaminophen	Acetaminophen results in decreased expression of APOC3 mRNA	26690555\|2906747
C006418	adrenocorticotropin zinc	adrenocorticotropin zinc results in increased expression of APOC3 mRNA	19920212
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of APOC3 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of APOC3 mRNA	27153756
D000535	Aluminum	[APP protein modified form binds to Aluminum] which results in decreased expression of APOC3 mRNA	21298039
D001379	Azathioprine	Azathioprine results in decreased expression of APOC3 mRNA	22623647
C547126	AZM551248	AZM551248 results in decreased expression of APOC3 mRNA	22323515
C006703	benzo(b)fluoranthene	[Benzo(a)pyrene co-treated with benzo(b)fluoranthene] affects the expression of APOC3 mRNA	17690111
D001564	Benzo(a)pyrene	"[Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene] affects the expression of APOC3 mRNA"	17690111
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with 1-methylphenanthrene] affects the expression of APOC3 mRNA	17690111
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with benzo(b)fluoranthene] affects the expression of APOC3 mRNA	17690111
D001564	Benzo(a)pyrene	"[Benzo(a)pyrene co-treated with dibenzo(a,l)pyrene] affects the expression of APOC3 mRNA"	17690111
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of APOC3 mRNA	17690111
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of APOC3 mRNA	21632981\|2231617
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of APOC3 mRNA	19770486\|2222880
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of APOC3 mRNA"	26238291
C095105	bexarotene	bexarotene results in decreased expression of APOC3 mRNA	16648578
D001629	Bezafibrate	Bezafibrate results in decreased expression of APOC3 protein	11164425\|9041378
D001629	Bezafibrate	Bezafibrate results in decreased expression of APOC3 mRNA	12782154\|1912461
D001629	Bezafibrate	PPARA protein affects the reaction [Bezafibrate results in decreased expression of APOC3 mRNA]	12782154
D001629	Bezafibrate	PPARD protein affects the reaction [Bezafibrate results in decreased expression of APOC3 mRNA]	12782154
D001629	Bezafibrate	Bezafibrate results in decreased expression of APOC3 mRNA	8847480
D001629	Bezafibrate	Bezafibrate results in decreased expression of APOC3 protein	8847480
C543008	bis(4-hydroxyphenyl)sulfone	[Dietary Fats co-treated with bis(4-hydroxyphenyl)sulfone] affects the expression of APOC3 mRNA	27241191
C006780	bisphenol A	bisphenol A results in decreased expression of APOC3 mRNA	28483554
C006780	bisphenol A	bisphenol A results in decreased expression of APOC3 mRNA	25181051
C032036	bromobenzene	bromobenzene results in decreased expression of APOC3 mRNA	12628495
C018475	butyraldehyde	butyraldehyde results in decreased expression of APOC3 mRNA	26079696
D002110	Caffeine	[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein	16324916
D002122	Calcium Chloride	Calcium Chloride results in increased expression of APOC3 protein	25824407
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of APOC3 mRNA	15963342
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of APOC3 mRNA	16239168
D002791	Cholesterol, Dietary	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOC3 mRNA"	19509184
D008076	Cholesterol, HDL	"APOC3 gene polymorphism affects the abundance of Cholesterol, HDL"	16030523
C074702	chromium hexavalent ion	chromium hexavalent ion affects the expression of APOC3 mRNA	28472532
D002994	Clofibrate	Clofibrate results in decreased expression of APOC3 mRNA	12851107\|8847480
D002994	Clofibrate	Clofibrate results in decreased expression of APOC3 protein	8847480
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of APOC3 mRNA	24386269
D003300	Copper	APOC3 protein binds to Copper	23896426
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of APOC3 mRNA	19549813
C057862	cyanoginosin LR	cyanoginosin LR affects the expression of APOC3 protein	26984711
D016572	Cyclosporine	Cyclosporine results in decreased expression of APOC3 mRNA	20106945\|2556210
D003630	Daunorubicin	Daunorubicin results in increased expression of APOC3 protein	7637207
D003907	Dexamethasone	Dexamethasone results in increased expression of APOC3 mRNA	11162775
D003907	Dexamethasone	pirinixic acid inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]	11162775
D003907	Dexamethasone	Dexamethasone results in increased expression of APOC3 mRNA	20032058
D003907	Dexamethasone	Testosterone inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]	20032058
C041517	dibenzo(a,l)pyrene	"[Benzo(a)pyrene co-treated with dibenzo(a,l)pyrene] affects the expression of APOC3 mRNA"	17690111
D002945	Cisplatin	Cisplatin results in decreased expression of APOC3 mRNA	11099651
D004041	Dietary Fats	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOC3 mRNA"	19509184
D004041	Dietary Fats	Dietary Fats affects the expression of APOC3 mRNA	18457598
D004041	Dietary Fats	[Dietary Fats co-treated with bis(4-hydroxyphenyl)sulfone] affects the expression of APOC3 mRNA	27241191
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of APOC3 mRNA	21527772
C015835	dimethyl-4-toluidine	dimethyl-4-toluidine results in decreased expression of APOC3 mRNA	27638505
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]"	16297877
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal results in increased expression of APOC3 mRNA"	16297877
D004365	Drugs, Chinese Herbal	"PPARA protein affects the reaction [Drugs, Chinese Herbal inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]"	16297877
D004365	Drugs, Chinese Herbal	"PPARA protein affects the reaction [Drugs, Chinese Herbal results in increased expression of APOC3 mRNA]"	16297877
D004809	Ephedrine	[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein	16324916
D000431	Ethanol	Ethanol results in increased expression of APOC3 mRNA	17920746
D011345	Fenofibrate	Fenofibrate affects the expression of APOC3 mRNA	20801182
D011345	Fenofibrate	Fenofibrate results in decreased expression of APOC3 mRNA	10799317\|8847480
D011345	Fenofibrate	Fenofibrate results in decreased expression of APOC3 protein	8847480
D058607	Fibric Acids	Fibric Acids results in decreased expression of APOC3	8847480
D058607	Fibric Acids	[Fibric Acids results in decreased expression of APOC3] which results in decreased abundance of Triglycerides	8847480
D058607	Fibric Acids	[Fibric Acids binds to and results in increased activity of PPARA protein] which results in decreased expression of APOC3	16511610
D058607	Fibric Acids	Fibric Acids results in decreased expression of APOC3	11123853
D058607	Fibric Acids	[[Fibric Acids results in increased expression of LPL] co-treated with [Fibric Acids results in decreased expression of APOC3]] results in decreased abundance of Triglycerides	11123853
C007738	fluoranthene	[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of APOC3 mRNA	17690111
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in decreased expression of APOC3 mRNA	17070881
D005632	Fructose	"[Fructose co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of APOC3 mRNA"	19509184
C039281	furan	furan results in decreased expression of APOC3 mRNA	15120968\|2553966
D015248	Gemfibrozil	Gemfibrozil results in decreased expression of APOC3 mRNA	8847480
D015248	Gemfibrozil	Gemfibrozil results in decreased expression of APOC3 protein	8847480
C055328	ginsenoside Rf	ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]	16297877
C055328	ginsenoside Rf	ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]	16297877
C055328	ginsenoside Rf	ginsenoside Rf results in decreased expression of APOC3 protein	16297877
C055328	ginsenoside Rf	ginsenoside Rf results in increased expression of APOC3 mRNA	16297877
C055328	ginsenoside Rf	PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]	16297877
C055328	ginsenoside Rf	PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA]	16297877
D036145	Ginsenosides	Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]	16297877
D036145	Ginsenosides	Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]	16297877
D036145	Ginsenosides	Ginsenosides results in decreased expression of APOC3 protein	16297877
D036145	Ginsenosides	Ginsenosides results in increased expression of APOC3 mRNA	16297877
D036145	Ginsenosides	PPARA protein affects the reaction [Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]	16297877
D036145	Ginsenosides	PPARA protein affects the reaction [Ginsenosides results in increased expression of APOC3 mRNA]	16297877
D017313	Fenretinide	Fenretinide results in increased expression of APOC3 mRNA	28973697
C029424	hydrazine	hydrazine results in decreased expression of APOC3 mRNA	15370871
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of APOC3 mRNA	20044591
C410337	K 7174	K 7174 results in decreased expression of APOC3 mRNA	24086573
C558899	lopinavir-ritonavir drug combination	lopinavir-ritonavir drug combination results in increased expression of APOC3 protein	12646808
D015122	Mercaptopurine	Mercaptopurine results in decreased expression of APOC3 mRNA	23358152
D008701	Methapyrilene	Methapyrilene results in decreased expression of APOC3 mRNA	15120968
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of APOC3 mRNA	23179753
C500085	muraglitazar	[Oleic Acid co-treated with muraglitazar] results in increased expression of APOC3 mRNA	24534255
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of APOC3 mRNA"	25620056
D009532	Nickel	APOC3 protein binds to Nickel	23896426
C028007	nickel monoxide	nickel monoxide results in increased expression of APOC3 mRNA	19167457
C464660	obeticholic acid	obeticholic acid results in decreased expression of APOC3 mRNA	27939613
D019301	Oleic Acid	[Oleic Acid co-treated with muraglitazar] results in increased expression of APOC3 mRNA	24534255
D019301	Oleic Acid	[Oleic Acid co-treated with rosiglitazone] results in increased expression of APOC3 mRNA	24534255
D019301	Oleic Acid	[Oleic Acid co-treated with tesaglitazar] results in increased expression of APOC3 mRNA	24534255
C076029	olanzapine	APOC3 gene polymorphism affects the susceptibility to olanzapine	17726453
C584865	perfluorononanoic acid	perfluorononanoic acid results in decreased expression of APOC3 mRNA	28049043
C584865	perfluorononanoic acid	PPARA gene mutant form inhibits the reaction [perfluorononanoic acid results in decreased expression of APOC3 mRNA]	28049043
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of APOC3 mRNA	17681415
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of APOC3 mRNA	19162173
C027579	periodate-oxidized adenosine	periodate-oxidized adenosine affects the expression of APOC3 mRNA	17097637
D010634	Phenobarbital	Phenobarbital results in decreased expression of APOC3 mRNA	19162173
C060836	pioglitazone	[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein	16324916
C006253	pirinixic acid	"Drugs, Chinese Herbal inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]"	16297877
C006253	pirinixic acid	ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]	16297877
C006253	pirinixic acid	ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]	16297877
C006253	pirinixic acid	Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]	16297877
C006253	pirinixic acid	Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]	16297877
C006253	pirinixic acid	[pirinixic acid co-treated with PPARA] results in decreased expression of APOC3 mRNA	20813756
C006253	pirinixic acid	pirinixic acid inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]	11162775
C006253	pirinixic acid	pirinixic acid results in decreased expression of APOC3 mRNA	11162775\|1629787
C006253	pirinixic acid	pirinixic acid results in decreased expression of APOC3 protein	16297877
C006253	pirinixic acid	"PPARA protein affects the reaction [Drugs, Chinese Herbal inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]"	16297877
C006253	pirinixic acid	PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]	16297877
C006253	pirinixic acid	PPARA protein affects the reaction [Ginsenosides inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]	16297877
C006253	pirinixic acid	PPARGC1B protein inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]	17932310
C006253	pirinixic acid	pirinixic acid results in decreased expression of APOC3 mRNA	19162173\|2248451
D059808	Polyphenols	Polyphenols results in decreased expression of APOC3 mRNA	16293270
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of APOC3 mRNA	23608068
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in decreased expression of APOC3 mRNA	19162173
D011341	Probucol	Probucol results in decreased expression of APOC3 mRNA	16292755
D011794	Quercetin	Quercetin affects the expression of APOC3 mRNA	21632981
C089730	rosiglitazone	[Oleic Acid co-treated with rosiglitazone] results in increased expression of APOC3 mRNA	24534255
C089730	rosiglitazone	rosiglitazone results in decreased expression of APOC3 mRNA	10799317
D019821	Simvastatin	Simvastatin results in decreased expression of APOC3 mRNA	25055962
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of APOC3 protein	28918527
D053260	Soot	Soot results in increased expression of APOC3 mRNA	26551751
C501413	tesaglitazar	[Oleic Acid co-treated with tesaglitazar] results in increased expression of APOC3 mRNA	24534255
D013739	Testosterone	Testosterone inhibits the reaction [Dexamethasone results in increased expression of APOC3 mRNA]	20032058
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of APOC3 mRNA	26238291
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of APOC3 mRNA	28213091
D013750	Tetrachloroethylene	Tetrachloroethylene results in decreased expression of APOC3 mRNA	28973375
D013752	Tetracycline	Tetracycline results in decreased expression of APOC3 mRNA	16917069
C017953	tetramethylpyrazine	tetramethylpyrazine results in decreased expression of APOC3 mRNA	15520497
C009495	titanium dioxide	titanium dioxide results in decreased expression of APOC3 mRNA	23409001\|2355797
C034697	transplatin	transplatin results in decreased expression of APOC3 mRNA	11099651
D014280	Triglycerides	APOC3 gene SNP affects the abundance of Triglycerides	24097064
D014280	Triglycerides	[Fibric Acids results in decreased expression of APOC3] which results in decreased abundance of Triglycerides	8847480
D014280	Triglycerides	[[Fibric Acids results in increased expression of LPL] co-treated with [Fibric Acids results in decreased expression of APOC3]] results in decreased abundance of Triglycerides	11123853
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of APOC3 mRNA"	26179874
D014520	Urethane	Urethane results in decreased expression of APOC3 mRNA	28818685
D014635	Valproic Acid	Valproic Acid affects the expression of APOC3 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of APOC3 mRNA	23179753\|2915479
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of APOC3 gene	25560391
D024483	Vitamin K 3	Vitamin K 3 affects the expression of APOC3 mRNA	20044591

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005543	phospholipid binding	-	IBA	21873635
GO:0005543	phospholipid binding	-	IDA	4066713 11060345
GO:0015485	cholesterol binding	-	IC	11162594
GO:0030234	enzyme regulator activity	-	IDA	11060345
GO:0055102	lipase inhibitor activity	-	IBA	21873635
GO:0055102	lipase inhibitor activity	-	IDA	182536 3973011 15576844 18635818
GO:0070653	high-density lipoprotein particle receptor binding	-	IBA	21873635
GO:0070653	high-density lipoprotein particle receptor binding	-	IPI	9254056

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001523	retinoid metabolic process	-	TAS	-
GO:0006641	triglyceride metabolic process	-	IMP	17142127
GO:0006869	lipid transport	-	IBA	21873635
GO:0007186	G-protein coupled receptor signaling pathway	-	IDA	16443932
GO:0010897	negative regulation of triglyceride catabolic process	-	IBA	21873635
GO:0010897	negative regulation of triglyceride catabolic process	-	IDA	3973011 18635818
GO:0010903	negative regulation of very-low-density lipoprotein particle remodeling	-	IC	18635818
GO:0010903	negative regulation of very-low-density lipoprotein particle remodeling	-	IDA	3973011
GO:0010916	negative regulation of very-low-density lipoprotein particle clearance	-	IBA	21873635
GO:0010916	negative regulation of very-low-density lipoprotein particle clearance	-	IDA	1917954
GO:0010987	negative regulation of high-density lipoprotein particle clearance	-	IBA	21873635
GO:0010987	negative regulation of high-density lipoprotein particle clearance	-	IMP	15778093
GO:0010989	negative regulation of low-density lipoprotein particle clearance	-	IBA	21873635
GO:0010989	negative regulation of low-density lipoprotein particle clearance	-	IMP	15778093
GO:0019433	triglyceride catabolic process	-	IDA	11060345
GO:0032489	regulation of Cdc42 protein signal transduction	-	IDA	16443932
GO:0033344	cholesterol efflux	-	IDA	11162594 16443932
GO:0033700	phospholipid efflux	-	IDA	11162594
GO:0034371	chylomicron remodeling	-	TAS	-
GO:0034375	high-density lipoprotein particle remodeling	-	IMP	17438339
GO:0034375	high-density lipoprotein particle remodeling	-	TAS	-
GO:0034378	chylomicron assembly	-	TAS	-
GO:0034379	very-low-density lipoprotein particle assembly	-	TAS	18399797
GO:0034382	chylomicron remnant clearance	-	IDA	4020294
GO:0042157	lipoprotein metabolic process	-	IEA	-
GO:0042632	cholesterol homeostasis	-	IBA	21873635
GO:0042632	cholesterol homeostasis	-	IMP	18767813
GO:0043691	reverse cholesterol transport	-	IC	17438339
GO:0045717	negative regulation of fatty acid biosynthetic process	-	IDA	11060345 18635818
GO:0045833	negative regulation of lipid metabolic process	-	IDA	182536
GO:0048261	negative regulation of receptor-mediated endocytosis	-	IDA	1917954
GO:0050995	negative regulation of lipid catabolic process	-	IDA	15576844
GO:0051005	negative regulation of lipoprotein lipase activity	-	IBA	21873635
GO:0051005	negative regulation of lipoprotein lipase activity	-	IDA	3973011 11060345 18635818
GO:0060621	negative regulation of cholesterol import	-	IMP	15778093
GO:0070328	triglyceride homeostasis	-	IBA	21873635
GO:0070328	triglyceride homeostasis	-	IMP	18767813

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	TAS	-
GO:0005615	extracellular space	-	IDA	11060345
GO:0005769	early endosome	-	TAS	-
GO:0034361	very-low-density lipoprotein particle	-	IBA	21873635
GO:0034361	very-low-density lipoprotein particle	-	IDA	3973011 16935699 17154273
GO:0034363	intermediate-density lipoprotein particle	-	IBA	21873635
GO:0034363	intermediate-density lipoprotein particle	-	IDA	17336988
GO:0034366	spherical high-density lipoprotein particle	-	IBA	21873635
GO:0034366	spherical high-density lipoprotein particle	-	IDA	17438339
GO:0042627	chylomicron	-	IBA	21873635
GO:0042627	chylomicron	-	IDA	8245722
GO:0062023	collagen-containing extracellular matrix	-	HDA	27068509 27559042
GO:0070062	extracellular exosome	-	HDA	23533145

KEGG ID	KEGG Term
hsa03320	PPAR signaling pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-1430728	Metabolism	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	TAS
R-HSA-196854	Metabolism of vitamins and cofactors	TAS
R-HSA-196854	Metabolism of vitamins and cofactors	IEA
R-HSA-2187338	Visual phototransduction	TAS
R-HSA-2187338	Visual phototransduction	IEA
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-372790	Signaling by GPCR	IEA
R-HSA-382551	Transport of small molecules	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-388396	GPCR downstream signalling	IEA
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-418594	G alpha (i) signalling events	IEA
R-HSA-6806667	Metabolism of fat-soluble vitamins	TAS
R-HSA-6806667	Metabolism of fat-soluble vitamins	IEA
R-HSA-8963888	Chylomicron assembly	TAS
R-HSA-8963898	Plasma lipoprotein assembly	TAS
R-HSA-8963899	Plasma lipoprotein remodeling	TAS
R-HSA-8963901	Chylomicron remodeling	TAS
R-HSA-8964058	HDL remodeling	TAS
R-HSA-975634	Retinoid metabolism and transport	TAS
R-HSA-975634	Retinoid metabolism and transport	IEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24656450	Genetic score based on high-risk genetic polymorphisms and early onset of ischemic heart disease in an Italian cohort of ischemic patients. (2014 May)	Vecoli C	Thromb Res
11714857	Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. (2001 Nov)	Pallaud C	J Lipid Res
12379174	Genetics, the environment, and lipid abnormalities. (2002 Nov)	Ordovas JM	Curr Cardiol Rep
21185820	APOC3 -482C>T polymorphism, circulating apolipoprotein C-III and smoking: interrelation and roles in predicting type-2 diabetes and coronary disease. (2011 Apr)	Onat A	Clin Biochem
11575217	[APOC3, CETP, beta-fibrinogen and MTHFR are genetic determinants of carotid intim-media thickness (Stanislas cohort)]. (2001 Aug)	Pallaud C	Arch Mal Coeur Vaiss
12006394	Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. (2002 May 1)	Tai ES	Arterioscler Thromb Vasc Biol
17016614	Genetic factors for obesity. (2006 Nov)	Yamada Y	Int J Mol Med
11270684	Variable effects of the APOC3-482C > T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. (2001 Feb)	Waterworth DM	Diabetologia
23883544	Renal insufficiency without albuminuria is associated with peripheral artery atherosclerosis and lipid metabolism disorders in patients with type 2 diabetes. (2013)	Yamashita T	J Atheroscler Thromb
11893778	Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. (2002 Mar)	Corella D	J Lipid Res
11116069	Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. (2000 Dec)	Waterworth DM	Arterioscler Thromb Vasc Biol
22460246	Influence of genetic variants in the apolipoprotein A5 and C3 gene on lipids, lipoproteins, and its association with coronary artery disease in Indians. (2010 Sep)	Bhanushali AA	J Community Genet
15576429	Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. (2005 Feb)	Olivieri O	Clin Chem
23377670	Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease. (2013 Jun)	Abd-El-Aziz TA	J Cardiovasc Transl Res
11286640	Genetic determinants of plasma triglycerides: impact of rare and common mutations. (2001 May)	Talmud PJ	Curr Atheroscler Rep
26387083	Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study. (2015 Sep 19)	Yang G	Lipids Health Dis
15983323	Effect of hepatic lipase -514C->T polymorphism and its interactions with apolipoprotein C3 -482C->T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in chinese type 2 diabetic patients. (2005 Jul)	Baum L	Diabetes Care
26824674	Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. (2016)	Wu Y	PLoS One
11359462	APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). (2001 May)	Pallaud C	Clin Genet
15488874	A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. (2004 Nov)	Liu S	Atherosclerosis
17367769	Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes. (2007 May 1)	Fiegenbaum M	Clin Chim Acta
25932792	Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. (2015 Jun)	Savinova OV	Atherosclerosis
12697301	Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. (2003 Apr 17)	Waterworth DM	Biochim Biophys Acta